Market Research Logo

Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2027

DelveInsight’s ‘Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Idiopathic Pulmonary Fibrosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Idiopathic Pulmonary Fibrosis Epidemiology
The Idiopathic Pulmonary Fibrosis (IPF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Idiopathic Pulmonary Fibrosis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Idiopathic Pulmonary Fibrosis Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, diagnosed prevalent cases, gender-specific cases, age-specific cases and severity specific prevalence) scenario of Idiopathic Pulmonary Fibrosis (IPF) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the total number of diagnosed prevalent population of Idiopathic Pulmonary Fibrosis was found to be 261,482, in the year 2016.

Report Scope
• The report covers detailed overview of Idiopathic Pulmonary Fibrosis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Idiopathic Pulmonary Fibrosis in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by sub-type i.e., Age-specific & Gender-specific Idiopathic Pulmonary Fibrosis and severity specific in 7MM

Key strengths
• 10 Year Forecast of Idiopathic Pulmonary Fibrosis epidemiology
• 7MM Coverage
• Total Prevalent Cases of IPF
• Prevalent Cases according to segmentation: Age-specific, Gender- specific prevalence and Severity-specific
• Diagnosed cases of IPF

Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population


1. Key Insights
2. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
2.1. Introduction
2.2. Staging of IPF
2.3. Risk Factors & Disease Causes
2.4. Symptoms
2.5. Pathogenesis
2.6. Diagnosis
3. Epidemiology and Patient Population
3.1. Key Findings
3.2. 7 MM Prevalent Population of IPF
3.3. Country Wise-Epidemiology of IPF
3.3.1. United States
3.3.2. Prevalent cases of IPF in the United States
3.3.3. Prevalent Population of IPF by severity
3.3.4. Gender-Specific IPF Prevalence
3.3.5. Age-Specific IPF Prevalence
3.3.6. EU5
3.3.7. Prevalent Population of IPF in EU5
3.3.8. France
3.3.9. Prevalent Population of IPF
3.3.10. Prevalent Population of IPF by severity
3.3.11. Gender-Specific IPF Prevalence
3.3.12. Age-Specific IPF Prevalence
3.3.13. Germany
3.3.14. Prevalent Population of IPF
3.3.15. Prevalent Population of IPF by severity
3.3.16. Gender-Specific IPF Prevalence
3.3.17. Age-Specific IPF Prevalence
3.3.18. Italy
3.3.19. Prevalent Population of IPF
3.3.20. Prevalent Population of IPF by severity
3.3.21. Gender-Specific IPF Prevalence
3.3.22. Age-Specific IPF Prevalence
3.3.23. Spain
3.3.24. Prevalent Population of IPF
3.3.25. Prevalent Population of IPF by severity
3.3.26. Gender-Specific IPF Prevalence
3.3.27. Age-Specific IPF Prevalence
3.3.28. United Kingdom
3.3.29. Prevalent Population of IPF
3.3.30. Prevalent Population of IPF by severity
3.3.31. Gender-Specific IPF Prevalence
3.3.32. Age-Specific IPF Prevalence
3.3.33. Japan
3.3.34. Prevalent Population of IPF
3.3.35. Prevalent Population of IPF by severity
3.3.36. Gender-SPECIFIC IPF Prevalence
3.3.37. Age-Specific IPF Prevalence
4. Appendix
4.1. Report Methodology
5. DelveInsight Capabilities
6. Disclaimer
7. About DelveInsight
List of Tables and Figures
Table 1: Expected 1-year probability of death in patients with Idiopathic Pulmonary Fibrosis (IPF)
Table 2: The GAP (Gender, Age and Physiology) score
Table 3: The GAP index and staging system
Table 4: 7 MM, Historical & Forecasted IPF Prevalence, 2016-2027
Table 5: The United States, Historical & Forecasted IPF Prevalence, 2016-2027
Table 6: The United States, Historical & Forecasted Prevalence of IPF by severity, 2016-2027
Table 7: The United States, Gender-Specific IPF Prevalence, 2016-2027
Table 8: The United States, Age-Specific IPF Prevalence, 2016-2027
Table 9: EU5, Historical & Forecasted IPF Prevalence, 2016-2027
Table 10: France, Historical & Forecasted IPF Prevalence, 2016-2027
Table 11: France, Historical & Forecasted Prevalence of IPF by severity, 2016-2027
Table 12: France, Gender-Specific IPF Prevalence, 2016-2027
Table 13: France, Age-Specific IPF Prevalence, 2016-2027
Table 14: Germany, Historical & Forecasted IPF Prevalence, 2016-2027
Table 15: Germany, Historical & Forecasted Prevalence of IPF by severity, 2016-2027
Table 16: Germany, Gender-Specific IPF Prevalence, 2016-2027
Table 17: Germany, Age-Specific IPF Prevalence, 2016-2027
Table 18: Italy, Historical & Forecasted IPF Prevalence, 2016-2027
Table 19: Italy, Historical & Forecasted Prevalence of IPF by severity, 2016-2027
Table 20: Italy, Gender-Specific IPF Prevalence, 2016-2027
Table 21: Italy, Age-Specific IPF Prevalence, 2016-2027
Table 22: Spain, Historical & Forecasted IPF Prevalence, 2016-2027
Table 23: Spain, Historical & Forecasted Prevalence of IPF by severity, 2016-2027
Table 24: Spain, Gender-Specific IPF Prevalence, 2016-2027
Table 25: Spain, Age-Specific IPF Prevalence, 2016-2027
Table 26: The United Kingdom, Historical & Forecasted IPF Prevalence, 2016-2027
Table 27: The United Kingdom, Historical & Forecasted Prevalence of IPF by severity, 2016-2027
Table 28: The United Kingdom, Gender-Specific IPF Prevalence, 2016-2027
Table 29: The United Kingdom, Age-Specific IPF Prevalence, 2016-2027
Table 30: Japan, Historical & Forecasted IPF Prevalence, 2016-2027
Table 31: Japan, Historical & Forecasted Prevalence of IPF by severity, 2016-2027
Table 32: Japan, Gender-Specific IPF Prevalence, 2016-2027
Table 33: Japan, Age-Specific IPF Prevalence, 2016-2027
Figure 1: Risk factors associated with Idiopathic Pulmonary Fibrosis (IPF)
Figure 2: IPF associated clubbing of the fingertips
Figure 3: Stages of pathogenesis of IPF
Figure 4: A schematic representing the current model for the pathogenesis of IPF
Figure 5: Possible mechanisms of fibrogenesis in IPF
Figure 6: Chest radiograph of a patient with IPF showing bilateral lower lobe reticular opacities (red circles)
Figure 7: Subpleural honeycombing in IPF diagnosed patients
Figure 8: Diagnostic algorithm of Patients with suspected IPF
Figure 9: 7 MM, Historical & Forecasted IPF Prevalence, 2016-2027
Figure 10: The United States, Historical & Forecasted IPF Prevalence, 2016-2027
Figure 11: The United States, Historical & Forecasted Prevalence of IPF by severity, 2016-2027
Figure 12: The United States, Gender-Specific IPF Prevalence, 2016-2027
Figure 13: The United States, Age-Specific IPF Prevalence, 2016-2027
Figure 14: EU5, Historical & Forecasted IPF Prevalence, 2016-2027
Figure 15: France, Historical & Forecasted IPF Prevalence, 2016-2027
Figure 16: France, Historical & Forecasted Prevalence of IPF by severity, 2016-2027
Figure 17: France, Gender-Specific IPF Prevalence, 2016-2027
Figure 18: France, Age-specific IPF Prevalence, 2016-2027
Figure 19: Germany, Historical & Forecasted IPF Prevalence, 2016-2027
Figure 20: Germany, Historical & Forecasted Prevalence of IPF by severity, 2016-2027
Figure 21: Germany, Gender-Specific IPF Prevalence, 2016-2027
Figure 22: Germany, Age-Specific IPF Prevalence, 2016-2027
Figure 23: Italy, Historical & Forecasted IPF Prevalence, 2016-2027
Figure 24: Italy, Historical & Forecasted Prevalence of IPF by severity, 2016-2027
Figure 25: Italy, Gender-Specific IPF Prevalence, 2016-2027
Figure 26: Italy, Age-Specific IPF Prevalence, 2016-2027
Figure 27: Spain, Historical & Forecasted IPF Prevalence, 2016-2027
Figure 28: Spain, Historical & Forecasted Prevalence of IPF by severity, 2016-2027
Figure 29: Spain, Gender-Specific IPF Prevalence, 2016-2027
Figure 30: Spain, Age-Specific IPF Prevalence, 2016-2027
Figure 31: The United Kingdom, Historical & Forecasted IPF Prevalence, 2016-2027
Figure 32: The United Kingdom, Historical & Forecasted Prevalence of IPF by severity, 2016-2027
Figure 33: The United Kingdom, Gender-Specific IPF Prevalence, 2016-2027
Figure 34: The United Kingdom, Age-Specific IPF Prevalence, 2016-2027
Figure 35: Japan, Historical & Forecasted IPF Prevalence, 2016-2027
Figure 36: Japan, Historical & Forecasted Prevalence of IPF by severity, 2016-2027
Figure 37: Japan, Gender-Specific IPF Prevalence, 2016-2027
Figure 38: Japan, Age-Specific IPF Prevalence, 2016-2027

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report